JOMES adheres to the guidelines and best practices published by professional organizations, including the ICMJE Recommendations and the Principles of Transparency and Best Practice in Scholarly Publishing (joint statement by the Committee on Publication Ethics, COPE; the Directory of Open Access Journals, DOAJ; the World Association of Medical Editors, WAME; and the Open Access Scholarly Publishers Association, OASPA; https://doaj.org/bestpractice). Furthermore, all processes of handling research and publication misconduct shall follow the applicable COPE flowchart (https://publicationethics.org/resources/flowcharts). JOMES requests that all authors comply with research and publication ethics policies.
1) Conflict of interest statement
A conflict of interest exists when a person's interpretation of data or presentation of information could be influenced by a personal or financial relationship with other people or organizations. Authors must disclose any financial competing interests. Authors should also reveal any nonfinancial competing interests that may cause them embarrassment were they to become public after publication of the manuscript. Authors are required to complete a declaration of competing interests. All competing interests that are declared will be listed at the end of published articles.
2) Statement of informed consent and institutional review board approval
Clinical research should be conducted in accordance with the World Medical Association’s Declaration of Helsinki (https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects).
Clinical studies that do not meet the Helsinki Declaration will not be considered for publication.
For clinical studies with human subjects, there should be a certificate, agreement, or approval by the Institutional Review Board (IRB) of the author's affiliated institution. If necessary, the editor or reviewers may request copies of these documents to resolve questions about IRB approval and study conduct. For humans, identifiable information, such as patients' names, initials, hospital numbers, dates of birth, or other protected health care information, should not be disclosed. Copies of written informed consent forms should be kept for studies on human subjects. This information should be specified in the Methods section of the manuscript. For animal subjects, authors must state that their care was in accordance with national laws and institutional regulations. The ethical treatment of all experimental animals must conform to the guidelines provided by the Institutional Animal Care and Use Committee (IACUC).
3) Authorship and author's responsibility
Authorship credit should be based on: (1) substantial contributions to the conception and design of the study, acquisition of data, and/or analysis and interpretation of data; (2) participation in drafting of the article or revising it critically for important intellectual content; (3) the provision of final approval of the version to be published; and (4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of it are appropriately investigated and resolved. Every author should meet all four of these conditions.
The corresponding author takes primary responsibility for communication with the journal during manuscript submission, peer review, and publication and typically ensures that all of the journal's administrative requirements, such as providing details of authorship, ethics committee approval, clinical trial registration documentation, and gathering conflict of interest forms and statements, are properly completed, although these duties may be delegated to one or more coauthors. The corresponding author should be available throughout the submission and peer review process to respond to editorial queries in a timely way and should be available after publication to respond to critiques of the work and cooperate with any requests from the journal for data or additional information should questions arise after publication. Authors are responsible for the whole content of each article.
After initial submission of a manuscript, any changes in authorship (adding author(s), deleting author(s), or rearranging the order of author(s)) must be explained in a letter to the editor from the authors concerned. This letter must be signed by all authors of the paper. JOMES does not correct authorship after acceptance for publication unless a mistake has been made by the editorial staff.
4) Originality and duplicate publication
Manuscripts that have already been published in other journals or this journal shall not be published in duplication. If an article containing similar information has already been published in other journals, a copy of the article should be submitted with the manuscript. In this case, the editorial board of JOMES will first determine whether the manuscript had already been published elsewhere and then later review it to decide if it is suitable for publication in this journal. A manuscript that has already been published in this journal may not be published in other journals without the permission of the editorial board of JOMES. Figures and tables of this journal can be used freely if the original source is verified according to the Creative Commons Attribution Noncommercial License. It is mandatory for all authors to resolve any copyright issues when citing a figure or table from another journal that is not open access.
5) Process for managing research and publication misconduct
When JOMES faces suspected cases of research and publication misconduct such as duplicate publication, plagiarism, fraudulent or fabricated data, changes in authorship, undisclosed conflicts of interest, ethical problems with a submitted manuscript, a reviewer who has appropriated an author's idea or data, or a complaint against the editors, the resolution process will be as is presented in a flowchart provided by the Committee on Publication Ethics (http://publicationethics.org/resources/flowcharts). All discussion and decisions on the suspected cases are overseen by the JOMES Editorial Board.
6) Editorial responsibilities
The editorial board will continuously work to monitor/safeguard publication ethics: provide guidelines for retracting articles; maintain the integrity of the academic record; prevent business needs from compromising intellectual and ethical standards; publish corrections, clarifications, retractions, and apologies when needed; and ensure the absence of plagiarism and fraudulent data. The editorial board checks manuscripts to confirm the originality of the text through Similarity Check (Powered by iThenticate). If the value of similarity index is unexpectedly high, the manuscript will be screened more precisely for plagiarism or duplicate publication. Editors maintain the following: the responsibility and authority to reject/accept an article; have no conflicts of interest with respect to the articles they reject/accept; accept a paper when reasonably certain of its appropriateness; promote the publication of a correction or retraction when errors are found; and preserve the anonymity of reviewers.
All manuscripts from editors, employees, or members of the editorial board are processed same to other unsolicited manuscripts. During the review process, submitters will not engage in the decision process. Editors will not handle their own manuscripts although they are commissioned ones.
7) Clinical trials registry
We strongly recommend, as a condition of consideration for publication, that a study be registered in a public trials registry. Trials must be registered at or before the onset of patient enrollment. This policy applies to any clinical trial starting enrollment after January 1, 2006. For trials that began enrollment before this date, we request that registration be done by April 1, 2006, before considering the trial for publication. We define a clinical trial as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as studies on pharmacokinetics or major toxicity (e.g., phase 1 trials), are exempt.
Registries include: (1) the registry sponsored by the United States National Library of Medicine (NLM) (https://www.clinicaltrials.gov); (2) the International Standard Randomized Controlled Trial Number Registry (http://www.controlled-trials.com); (3) the European Clinical Trials Database (https://eudract.ema.europa.eu); and (4) the Clinical Research Information Service-Republic of Korea (https://cris.nih.go.kr/cris). For specific study designs, such as randomized controlled studies, studies of diagnostic accuracy, meta-analyses, observational studies, and non-randomized studies, authors are encouraged to also consult the reporting guidelines relevant to their specific research design. Good sources of reporting guidelines are the EQUATOR Network (https://www.equator-network.org/) and the NLM (https://www.nlm.nih.gov/services/research_report_guide.html).